Indivior PLC (NASDAQ:INDV) Receives Average Rating of “Buy” from Analysts

Indivior PLC (NASDAQ:INDV) has been assigned an average rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $39.3333.

Several research analysts have recently weighed in on INDV shares. HC Wainwright upped their price objective on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Weiss Ratings downgraded shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, March 17th. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Northland Securities set a $50.00 price objective on Indivior in a research report on Tuesday, January 20th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $36.00 target price on shares of Indivior in a research note on Wednesday, December 3rd.

Insider Transactions at Indivior

In related news, Director Mark Stejbach purchased 775 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director owned 16,847 shares in the company, valued at approximately $596,215.33. This represents a 4.82% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David E. Wheadon purchased 1,771 shares of the stock in a transaction on Monday, January 5th. The stock was bought at an average cost of $35.39 per share, for a total transaction of $62,675.69. Following the completion of the acquisition, the director owned 14,395 shares in the company, valued at approximately $509,439.05. This trade represents a 14.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders acquired 5,842 shares of company stock valued at $203,342.

Institutional Investors Weigh In On Indivior

A number of institutional investors have recently made changes to their positions in the company. Rockefeller Capital Management L.P. grew its position in shares of Indivior by 512.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after purchasing an additional 1,076 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in Indivior by 72.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after purchasing an additional 460 shares during the period. Virtu Financial LLC acquired a new position in Indivior in the 4th quarter valued at $344,000. Invesco Ltd. grew its holdings in Indivior by 274.6% in the 4th quarter. Invesco Ltd. now owns 286,689 shares of the company’s stock valued at $10,286,000 after buying an additional 210,150 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new position in Indivior during the 4th quarter worth $274,000. Institutional investors own 60.33% of the company’s stock.

Indivior Stock Performance

Shares of INDV opened at $28.97 on Friday. The firm has a market cap of $3.62 billion, a P/E ratio of 17.66 and a beta of 0.83. Indivior has a twelve month low of $8.64 and a twelve month high of $38.00. The firm’s 50 day moving average price is $32.80 and its two-hundred day moving average price is $31.00.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Friday, February 27th. The company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.17. The business had revenue of $358.00 million for the quarter, compared to analyst estimates of $305.62 million. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. On average, sell-side analysts anticipate that Indivior will post 1.22 earnings per share for the current fiscal year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.